(Neo)adjuvant approaches: pavement on the road to cure-breast cancer

被引：1

作者：

Klocker, Eva Valentina ^{[1
]}

机构：

[1] Med Univ Graz, Dept Oncol, Auenbruggerpl 15, A-8036 Graz, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2024年 / 17卷 / 01期

关键词：

Early breast cancer; Treatment; Neoadjuvant and adjuvant strategies; OPEN-LABEL; TRASTUZUMAB; MULTICENTER; PERTUZUMAB; NERATINIB; EFFICACY; THERAPY; EXTENET; SAFETY;

D O I：

10.1007/s12254-023-00942-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

During the past few decades, major advances have been achieved in the treatment of early breast cancer (BC) resulting in improvements of inavasive disease free survival and overall survival. New treatment substances have been established in neoadjuvant and adjuvant settings. On the other hand, deescalation strategies are studied to get more tailored treatment concepts.

引用

页码：6 / 9

页数：4

共 29 条

[1] Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update [J].

Andre, Fabrice ;

Ismaila, Nofisat ;

Allison, Kimberly H. ;

Barlow, William E. ;

Collyar, Deborah E. ;

Damodaran, Senthil ;

Henry, N. Lynn ;

Jhaveri, Komal ;

Kalinsky, Kevin ;

Kuderer, Nicole M. ;

Litvak, Anya ;

Mayer, Erica L. ;

Pusztai, Lajos ;

Raab, Rachel ;

Wolff, Antonio C. ;

Stearns, Vered .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) :1816-+

[2]

[Anonymous], ABCSG 45 UB

[3] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer [J].

Cardoso, F. ;

McArthur, H. L. ;

Schmid, P. ;

Cortes, J. ;

Harbeck, N. ;

Telli, M. L. ;

Cescon, D. W. ;

O'Shaughnessy, J. ;

Fasching, P. ;

Shao, Z. ;

Loirat, D. ;

Park, Y. H. ;

Fernandez, M. E. Gonzalez ;

Liu, Z. ;

Yasojima, H. ;

Ding, Y. ;

Jia, L. ;

Karantza, V. V. ;

Tryfonidis, K. E. ;

Bardia, A. .

ANNALS OF ONCOLOGY, 2023, 34 :S1260-S1261

[4] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial [J].

Chan, Arlene ;

Moy, Beverly ;

Mansi, Janine ;

Ejlertsen, Bent ;

Holmes, Frankie Ann ;

Chia, Stephen ;

Iwata, Hiroji ;

Gnant, Michael ;

Loibl, Sibylle ;

Barrios, Carlos H. ;

Somali, Isil ;

Smichkoska, Snezhana ;

Martinez, Noelia ;

Alonso, Mirta Garcia ;

Link, John S. ;

Mayer, Ingrid A. ;

Cold, Soren ;

Murillo, Serafin Morales ;

Senecal, Francis ;

Inoue, Kenichi ;

Ruiz-Borrego, Manuel ;

Hui, Rina ;

Denduluri, Neelima ;

Patt, Debra ;

Rugo, Hope S. ;

Johnston, Stephen R. D. ;

Bryce, Richard ;

Zhang, Bo ;

Xu, Feng ;

Wong, Alvin ;

Martin, Miguel .

CLINICAL BREAST CANCER, 2021, 21 (01) :80-+

[5] Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].

Chan, Arlene ;

Delaloge, Suzette ;

Holmes, Frankie A. ;

Moy, Beverly ;

Iwata, Hiroji ;

Harvey, Vernon J. ;

Robert, Nicholas J. ;

Silovski, Tajana ;

Gokmen, Erhan ;

von Minckwitz, Gunter ;

Ejlertsen, Bent ;

Chia, Stephen K. L. ;

Mansi, Janine ;

Barrios, Carlos H. ;

Gnant, Michael ;

Buyse, Marc ;

Gore, Ira ;

Smith, John, II ;

Harker, Graydon ;

Masuda, Norikazu ;

Petrakova, Katarina ;

Guerrero Zotano, Angel ;

Iannotti, Nicholas ;

Rodriguez, Gladys ;

Tassone, Pierfrancesco ;

Wong, Alvin ;

Bryce, Richard ;

Ye, Yining ;

Yao, Bin ;

Martin, Miguel .

LANCET ONCOLOGY, 2016, 17 (03) :367-377

[6] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[7] 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). [J].

Cortes, Javier ;

Perez-Garcia, Jose Manuel ;

Ruiz-Borrego, Manuel ;

Stradella, Agostina ;

Bermejo, Begona ;

Escriva-de-Romani, Santiago ;

Calvo Martinez, Lourdes ;

Ribelles, Nuria ;

Cortes Salgado, Alfonso ;

Albacar, Cinta ;

Colleoni, Marco ;

Gebhart, Geraldine ;

Prat, Aleix ;

Khaldoun, Kerrou ;

Schmid, Peter ;

Di Cosimo, Serena ;

Popa, Crina ;

Alcala-Lopez, Daniel ;

Sampayo-Cordero, Miguel ;

Llombart-Cussac, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) :LBA506-LBA506

[8]

Daiichi Sankyo Inc., 2021, PHAS 3 MULT RAND OP

[9] Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer [J].

Geyer, C. E., Jr. ;

Garber, J. E. ;

Gelber, R. D. ;

Yothers, G. ;

Taboada, M. ;

Ross, L. ;

Rastogi, P. ;

Cui, K. ;

Arahmani, A. ;

Aktan, G. ;

Armstrong, A. C. ;

Arnedos, M. ;

Balmana, J. ;

Bergh, J. ;

Bliss, J. ;

Delaloge, S. ;

Domchek, S. M. ;

Eisen, A. ;

Elsafy, F. ;

Fein, L. E. ;

Fielding, A. ;

Ford, J. M. ;

Friedman, S. ;

Gelmon, K. A. ;

Gianni, L. ;

Gnant, M. ;

Hollingsworth, S. J. ;

Im, S-A ;

Jager, A. ;

Lakhani, S. R. ;

Janni, W. ;

Linderholm, B. ;

Liu, T-W ;

Loman, N. ;

Korde, L. ;

Loibl, S. ;

Lucas, P. C. ;

Marme, F. ;

de Duenas, E. Martinez ;

McConnell, R. ;

Phillips, K-A ;

Piccart, M. ;

Rossi, G. ;

Schmutzler, R. ;

Senkus, E. ;

Shao, Z. ;

Sharma, P. ;

Singer, C. F. ;

Spanic, T. ;

Stickeler, E. .

ANNALS OF ONCOLOGY, 2022, 33 (12) :1250-1268

[10] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Roman, Laslo ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia ;

Szado, Tania ;

Ratnayake, Jayantha ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2012, 13 (01) :25-32

← 1 2 3 →